MUC16 and neoplasm: No correlation was established between the miR-200a expression in serum and the duration of overall or recurrence-free survival [30], tumour size [30, 57], serum Cancer antigen 125 (CA-125) [30, 57], the use of neoadjuvant treatment [30], tumour grade [56, 57] or the involvement of lymph nodes in the cancer process [35, 57].